Shares of Western Digital Corp (NASDAQ: WDC) are poised for further upside despite deteriorating NAND fundamentals, according to RBC Capital Markets.
Analyst Mitch Steves maintained an Outperform on Western Digital and increased the price target from $55 to $60.
RBC's bullish rating on Western Digital — despite the bearish views of many that the company could go bankrupt in a deteriorating NAND environment — is premised on three drivers, Steves said in a Tuesday note.
The drivers are improving PC demand, data center ramps and smartphone support emerging from Chinese handset players, the analyst said.
Steves said he sees an additional upside driver in the implied value of Western Digital's fab.
"If we look at their 230,000-270,000 wafer starts per month, we get to a valuation of around $10 billion for the equipment alone," he said.
This compares to the $14 billion to $15 billion market capitalization of Western Digital shares, Steves said.
Assuming a conservative implied value for the equipment alone at the company's NAND fabs, the analyst said the stock likely holds $12.50 in upside.
The company is likely to benefit from its ability to accelerate and further improve capital allocation; the better-than-feared NAND cycle; and its ability to sustain and expand leadership in enterprise drives, he said.
"With the acquisition of SNDK, we think WDC is positioned to transform into a medium agnostic storage provider."
The Price Action
Western Digital shares were down 0.87 percent at $51.14 at the time of publication Tuesday.
3 Reasons Why Goldman Turned Bearish On Seagate Technology
Sell-Side Trims Seagate Price Targets After Data Company Issues Weak Guidance
Photo courtesy of Western Digital.
Latest Ratings for WDC
|Apr 2019||RBC Capital||Maintains||Outperform||Outperform|
|Mar 2019||RBC Capital||Assumes||Outperform|
|Jan 2019||Evercore ISI Group||Downgrades||In-Line||Underperform|
View More Analyst Ratings for WDC
View the Latest Analyst Ratings
See more from Benzinga
- FDA Rejects Regulatory Filing For Zogenix Epilepsy Drug; GW Pharma Moves In Sympathy
- The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing
- Guggenheim Shares 3 Positives, 3 Negatives For Frontdoor Investors
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.